FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

Fatty acid synthase (FASN) is an attractive therapeutic target in non-alcoholic steatohepatitis (NASH) because it drives de novo lipogenesis and mediates pro-inflammatory and fibrogenic signaling. We therefore tested pharmacological inhibition of FASN in human cell culture and in three diet induced...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Farrell, Marie, Duke, Greg, Crowley, Richard, Buckley, Douglas, Martins, Eduardo B., Bhattacharya, Dipankar, Friedman, Scott L., Kemble, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485253/
https://www.ncbi.nlm.nih.gov/pubmed/36123383
http://dx.doi.org/10.1038/s41598-022-19459-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485253/
https://www.ncbi.nlm.nih.gov/pubmed/36123383
http://dx.doi.org/10.1038/s41598-022-19459-z

Ejemplares similares